Prelude Therapeutics Files 8-K Report

Ticker: PRLD · Form: 8-K · Filed: Sep 13, 2024 · CIK: 1678660

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

Prelude Therapeutics filed an 8-K, check for updates.

AI Summary

On September 13, 2024, Prelude Therapeutics Incorporated filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing signals that Prelude Therapeutics has made a regulatory submission to the SEC, which may contain important updates for investors regarding the company's operations or financial condition.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report, and the provided excerpt does not contain information about significant negative events, financial distress, or major strategic shifts.

Key Players & Entities

FAQ

What specific "Other Events" are being reported by Prelude Therapeutics?

The provided excerpt does not detail the specific "Other Events" being reported; it only lists the category of the filing.

What "Financial Statements and Exhibits" are included in this 8-K filing?

The excerpt mentions "Financial Statements and Exhibits" as an item of disclosure but does not list the specific documents or their contents.

When was this 8-K report filed with the SEC?

The report was filed on September 13, 2024.

What is Prelude Therapeutics Incorporated's principal executive office address?

The principal executive offices are located at 175 Innovation Boulevard, Wilmington, Delaware 19805.

What is the SEC file number for Prelude Therapeutics?

The SEC file number for Prelude Therapeutics is 001-39527.

Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-09-13 16:15:28

Key Financial Figures

Filing Documents

01 Other events

Item 8.01 Other events On September 13, 2024, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing the first interim clinical data from its Phase 1 open-label, dose-escalation trial of PRT3789, a novel, highly-selective SMARCA2 degrader. The press release was issued simultaneously with the previously announced oral presentation of an abstract regarding such data at the European Society of Medical Oncology (ESMO) Congress 2024. A copy of the press release is attached as Exhibit 99.1 to this report. Additionally, the Company hosted an investor webcast on September 13, 2024 at 12:00 p.m. EST. A copy of the presentation materials from the investor webcast is attached as Exhibit 99.2 to this report. In connection with the presentation of the clinical data, the Company has updated its corporate presentation. A copy of the updated corporate presentation is attached as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release 99.2 Webcast presentation 99.3 Corporate presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRELUDE THERAPEUTICS INCORPORATED Date: September 13, 2024 By: /s/ Bryant Lim Bryant Lim Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing